Your search for Warfarin returned 33 results

For warfarin-treated patients, carbamazepine co-treatment is associated with subtherapeutic anticoagulative effect and increased warfarin dose requirements, according to a study published online in the Journal of Thrombosis and Haemostasis.

Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding

Taking warfarin at the same time as glipizide or glimepiride may increase the risk of hospitalization, according to a study published online December 7 in The BMJ.

Among hospitalized patients, high-dose amoxicillin/clavulanate correlates with increased risk of over-anticoagulation when combined with warfarin.

Pharmacist-managed warfarin therapy (PMWT) is superior to a usual medical care (UMC) model for management of warfarin therapy, according to a new review.

Obese patients taking warfarin have a higher risk of experiencing a bleeding event compared to their normal-weight counterparts, a new study suggests.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Unstable anticoagulation predicts warfarin adverse effects regardless of time in therapeutic range.

In patients with atrial fibrillation taking warfarin, use of selective serotonin reuptake inhibitor (SSRI) medications is associated with an increased risk of major hemorrhage.

For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.